All news > Hot topics
News from Interphex 2011 | |
 |
in-Pharmatechnologist.com presents a round up of all the latest developments in pharmaceutical manufacturing, processing and production technologies that were unveiled at Interphex 2011. |
EMD Millipore talks single use technology at Interphex 2011
How have single-use technologies changed drug production? How do you dispose of a disposable technology? What will drive the market going forward? EMD Millipore answered these questions and more at Interphex 2011.
PTI and Nikka Densok team on lab-scale HVLD
PTI Inspection Systems and Nikka Densok USA have teamed up to take high-voltage leak detection (HVLD) from the factory floor to the pharmaceutical lab.
LB Bohle sees increasing demand for ‘try before you buy’ demos
LB Bohle says healthy level of demand for processing technology demos at its recently opened service centre is an indication of processing tech market recovery.
Patheon talks about backup manufacturing service at Interphex 2011
Contract manufacturing organisation (CMO) Patheon has launched a new ‘back up’ sterile manufacturing service to help drug firms cope with supply interruptions and, it hopes, attract new business.
PAT and QbD changing powder flow analysis says Freeman
Regulatory demands for ‘in process’ performance data have changed the pharma sector’s approach to materials analysis and enhanced the quality of the drugs it produces according to Freeman Technology.
Pharma future bright for Puerto Rico says PRIDCO
The pharmaceutical manufacturing sector in Puerto Rico will thrive because of and not in spite of changes to the country’s tax and incentive laws according to the Puerto Rico Industrial Development Company (PRIDCO).
ATMI unveils helium integrity testing for bioprocess vessels at Interphex 2011
ATMI LifeSciences has introduced a new method of integrity testing for its range of single-use bioprocess vessels that, it claims, will take QA in the biomanufacturing sector to a new level.
China’s booming pharma sector welcomes western investors
Double-digit growth in the Chinese pharmaceutical sector will increasingly make the nation a lucrative place for Western companies to do business, delegates heard at the InterPhex trade event in New York.
China's new approvals system brings outsourcing opportunity
A new, tougher approvals policy for pharmaceutical products in China will bring opportunities for Western contract companies able to help domestic firms meet the strict new rules, according to a seminar at InterPhex in New York.
Planning key to cell therapies' $6bn growth
Planning the commercial production and delivery of effective cell therapies will be key if the sector is to achieve forecast growth of $6bn within nine years, according to a seminar at the InterPhex trade event in New York City.
US FDA opens Interphex 2011 with presentation backing continuous manufacturing
The US FDA set out its support for properly planned continuous manufacturing during a fascinating opening presentation at the first day of Interphex 2011 in New York, US yesterday.
News from AAPS 2010 | |
 |
The in-Pharmatechnologist team went to the American Association of Pharmaceutical Scientists (AAPS) conference in New Orleans, US to cover all the breaking drug industry news and trends and speak with key pharmaceutical industry movers and shakers. For the full list of articles click the + More button below |
Metrics discusses benzophenone migration at AAPS
US Contract research laboratory Metrics reveals that benzophenone, a component used in varnish on labels, is able to migrate through HDPE bottles to reach the pills inside.
Multiple strategies needed to beat counterfeiters
Only multiple anti-counterfeiting strategies are able to beat increasingly sophisticated criminals, according to a seminar on anti-counterfeiting at the recent AAPS trade event in New Orleans.
Monographs, heavy metals and globalisation on USP agenda
Updating monographs, changing elemental impurity tests and globalisation were discussed by the USP at its workshop and in interviews with in-PharmaTechnologist.
Phase I environmental testing helps waste handling decisions
Performing environmental testing early in a molecule’s development and including data in tech transfers to CMOs helps ensure there is little mass loading from pilot and commercial plants.
Capsugel sees demand for capsule filling tech improve in 2010
Demand for high-end capsule filling technologies, particularly those used for early clinical development projects, has increased in 2010 according to Capsugel.
Anti-counterfeiting held back by self-interest & politics
Narrowly defined pharma self-interest and lack of coordinated political effort means, despite the best effort of some, the problem of counterfeiting may be worsening.
Control excipient reactivity with packaging & aluminium lakes
Aluminium lakes and in-liner packaging can, in some cases, be used to control reactive components in excipients and therefore overcome drug product instability.
Will & desire needed to drive adoption of real-time release
The knowledge and means are in place to implement real-time release (RTR), a PAT pioneer said at AAPS, but questions remain about whether pharma has the will and desire.
Millions of dollars wasted on failed recruitment
Poor recruitment practices cost the United States pharmaceutical industry millions of dollars, warns a leading US biopharma recruitment agency.
Nose-to-brain delivery possible but challenges remain
Nose-to-brain delivery can become a reality, even for molecules with high molecular weights, but barriers relating to administration and adsorption remain, according to a panel at AAPS.
Globalisation is biggest challenge for supply chain security, says USP
Globalisation is the main challenge to drug supply chain security according to USP scientist Desmond Hunt, who says greater collaboration is the key to maintaining product integrity
Industry, innovation & Viagra-stuffed teddies at AAPS
Last week everything from co-processed excipients to Viagra-stuffed teddies were discussed at AAPS 2010. Now, with the show having finished, we present our personal take on the event.
Partnerships needed to beat public health counterfeit threat
Combatting counterfeit drugs through forging stronger partnerships is beyond profit, it is about saving lives, AstraZeneca principal scientist Dr Michael Claybourn told a workshop on global drug quality at the AAPS annual meeting in New Orleans.
USP building database of fake & substandard meds
The USP is building a database of counterfeit essential medicines to support international drug procurement organisations, such as WHO, and the timely sharing of information between national regulators.
Spotlight
  FDA biosimilar guidance permits alternative drug delivery devicesThe FDA has said biosimilars can use different drug delivery devices than their reference products in its... |
Latest news
On your radar
Globalisation
Lifecycle management
- FDA biosimilar guidance permits alternative drug delivery devices
- Samsung and Quintiles' biosimilars JV teams with Biogen Idec
Counterfeiting
- Annual WHO meeting to tackle spread of substandard drugs
- FDA calls for more powers to adopt nationwide ePedigree
